359 related articles for article (PubMed ID: 12031925)
1. Relapse of chronic myeloid leukemia (CML) in lymphoid crisis after allogeneic bone marrow transplantation for CML in chronic phase with busulfan plus cyclophosphamide regimen.
Takami A; Chuhjo T; Nakao S
Haematologica; 2002 Jun; 87(6):659-61. PubMed ID: 12031925
[No Abstract] [Full Text] [Related]
2. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
3. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
[TBL] [Abstract][Full Text] [Related]
4. [Allogeneic bone marrow transplantation in myeloid leukemia: chemical conditioning, clinical course and results].
Glejzer O; Sedzimirska M; Tomaszewska-Toporska B; Tomeczko J; Kołodziej J; Pacuszko T; Was A; Bocheńska J; Jaźwiec B; Klimczak A
Acta Haematol Pol; 1992; 23(2 Suppl 1):49-59. PubMed ID: 1488872
[TBL] [Abstract][Full Text] [Related]
5. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
Przepiorka D; Khouri I; Thall P; Mehra R; Lee MS; Ippoliti C; Giralt S; Gajewski J; van Besien K; Andersson B; Körbling M; Deisseroth AB; Champlin R
Bone Marrow Transplant; 1999 May; 23(10):977-81. PubMed ID: 10373061
[TBL] [Abstract][Full Text] [Related]
6. Lymphoid blast crisis of chronic myelogenous leukemia occurring more than 11 years after receiving an allogeneic bone marrow transplant for chronic myelogenous leukemia in myeloid blast crisis at onset.
Fukuno K; Tsurumi H; Yamada T; Oyama M; Matsuyama T; Terakura S; Kodera Y; Moriwaki H
Bone Marrow Transplant; 2003 Feb; 31(3):211-3. PubMed ID: 12621483
[TBL] [Abstract][Full Text] [Related]
7. Busulfan/cyclophosphamide plus bone marrow transplantation is not sufficient to eradicate the malignant clone in juvenile chronic myelogenous leukemia.
Urban C; Schwinger W; Slavc I; Schmid C; Gamillscheg A; Lackner H; Hauer C; Pakisch B
Bone Marrow Transplant; 1990 May; 5(5):353-6. PubMed ID: 2190661
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic bone marrow transplantation following busulfan and 90 mg/kg of cyclophosphamide.
Avalos BR; Klein JL; Kapoor N; Copelan EA
Bone Marrow Transplant; 1993 Dec; 12(6):655-8. PubMed ID: 8136749
[TBL] [Abstract][Full Text] [Related]
9. Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results.
Gaziev D; Galimberti M; Polchi P; Angelucci E; Giardini C; Baronciani D; Andreani M; Persini B; Erer B; Sodani P; Manna M; Nicolini G; Visani G; Lucarelli G;
Bone Marrow Transplant; 2002 Jan; 29(1):1-8. PubMed ID: 11840137
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.
Brodsky I; Biggs JC; Szer J; Crilley P; Atkinson K; Downs K; Dodds A; Concannon AJ; Avalos BR; Tutschka P
Semin Oncol; 1993 Aug; 20(4 Suppl 4):27-31; quiz 32. PubMed ID: 8342072
[TBL] [Abstract][Full Text] [Related]
11. Results of allogeneic bone marrow transplant in chronic myeloid leukaemia following conditioning with busulfan and cyclophosphamide.
Saikia TK; Advani SH; Parikh PM; Bapna A; Somjee S; Mukhopadhyay A; Gopal R; Nair CN
J Assoc Physicians India; 1999 Aug; 47(8):770-3. PubMed ID: 10778619
[TBL] [Abstract][Full Text] [Related]
12. Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia.
Copelan EA; Crilley PA; Szer J; Dodds AJ; Stevenson D; Phillips G; Elder P; Nivison-Smith I; Avalos BR; Penza S; Topolsky D; Sobecks R; Kalaycio M; Bolwell BJ
Biol Blood Marrow Transplant; 2009 Jul; 15(7):851-5. PubMed ID: 19539217
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects.
Thall PF; Champlin RE; Andersson BS
Bone Marrow Transplant; 2004 Jun; 33(12):1191-9. PubMed ID: 15122310
[TBL] [Abstract][Full Text] [Related]
14. [Complete cytogenetic response obtained with unrelated donor lymphocyte infusion for relapse of chronic myeloid leukemia in blastic crisis after allogeneic bone marrow transplantation].
Fujimaki K; Maruta A; Yoshida M; Yamazaki E; Matsuzaki M; Fujisawa S; Kanamori H; Ishigatsubo Y
Rinsho Ketsueki; 2001 Mar; 42(3):204-8. PubMed ID: 11345783
[TBL] [Abstract][Full Text] [Related]
15. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
[TBL] [Abstract][Full Text] [Related]
17. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
Sloand E; Childs RW; Solomon S; Greene A; Young NS; Barrett AJ
Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990
[TBL] [Abstract][Full Text] [Related]
18. Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan.
Kim SE; Lee JH; Choi SJ; Lee JH; Ryu SG; Lee KH
Haematologica; 2005 Feb; 90(2):285-6. PubMed ID: 15710597
[TBL] [Abstract][Full Text] [Related]
19. [Allogeneic bone marrow transplantation for chronic myeloid leukemia: 118 cases analysis].
Liu D; Guo N; Zhang Y
Zhonghua Xue Ye Xue Za Zhi; 1999 Aug; 20(8):424-6. PubMed ID: 11721424
[TBL] [Abstract][Full Text] [Related]
20. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
